What is Constructive Bio?
Constructive Bio is at the forefront of synthetic biology, developing innovative platforms for creating entirely synthetic genomes and reprogramming the genetic code of living organisms. Their technology enables the production of programmable polymers and has yielded virus-resistant organisms. By transforming living cells into sustainable bio-factories, Constructive Bio aims to realize the future of sustainable materials and advanced therapies, positioning itself as a key player in the biotechnology sector.
How much funding has Constructive Bio raised?
Constructive Bio has raised a total of $73M across 2 funding rounds:
Angel/Seed
$15M
Series A
$58M
Angel/Seed (2022): $15M, investors not publicly disclosed
Series A (2024): $58M led by Ahren Innovation Capital, Fine Structure Ventures, NanoDimension, Paladin Capital Group, and Omx Ventures
Key Investors in Constructive Bio
Ahren Innovation Capital
Ahren Innovation Capital is a venture capital firm specializing in deep technology and deep science, providing patient and active capital to support transformational companies from pre-seed to pre-IPO stages across domains like Genetics & Platform Technologies.
Fine Structure Ventures
Fine Structure Ventures is a venture capital firm focused on investing in disruptive scientific and technological innovations, actively partnering with its portfolio companies to commercialize revolutionary technologies.
NanoDimension
ND Capital is a venture capital firm established in 2002 that focuses on investing in disruptive technologies across life, physical, and data sciences, supporting portfolio companies in attracting capital and talent.
What's next for Constructive Bio?
The recent major strategic investment, likely a Series A round given the context, signals a critical growth phase for Constructive Bio. This influx of capital is expected to accelerate the scaling of its proprietary technologies, expand its research and development capabilities, and potentially broaden its market reach. The company's focus on sustainable materials and novel therapies suggests a strategic direction towards addressing significant global challenges in manufacturing and healthcare, with future funding rounds likely aimed at further commercialization and market penetration.
See full Constructive Bio company page
